Group 1 - The company announced the cancellation of Mr. Zhou Hui's position as employee representative supervisor [2] - Ms. Wang Weiqian was elected as the employee director of the company's tenth board of directors, with a term consistent with the tenth board [2] - The employee representative meeting took place on December 10, 2025 [2]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), indicating a slight decline in stock price and mixed capital flow on December 10, 2025 [1][2] - As of December 10, 2025, Tongce Medical's stock closed at 41.18 yuan, down 0.77%, with a turnover rate of 1.01% and a trading volume of 45,300 hands, resulting in a transaction amount of 186 million yuan [1] - The capital flow data on December 10 shows a net outflow of 18.96 million yuan from main funds, accounting for 10.19% of the total transaction amount, while retail investors saw a net inflow of 10.10 million yuan, representing 5.43% of the total [1] Group 2 - In the third quarter of 2025, Tongce Medical reported a main revenue of 842 million yuan, an increase of 2.34% year-on-year, and a net profit attributable to shareholders of 192 million yuan, up 2.31% year-on-year [2] - The company's financial metrics for the first three quarters of 2025 include a total revenue of 2.29 billion yuan, a net profit of 514 million yuan, and a debt ratio of 25.1% [2] - The average target price set by institutions for Tongce Medical over the past 90 days is 52.88 yuan, with 4 buy ratings and 3 hold ratings from 7 institutions [2]

证券简称：通策医疗 证券代码：600763 编号：临 2025-034 王维倩女士原为公司第十届董事会非职工董事，本次选举任期开始后，变更为公 司第十届董事会职工董事，公司第十届董事会构成人员不变。公司第十届董事会中兼 任公司高级管理人员以及由职工代表担任的董事人数总计未超过公司董事总数的二 分之一。 特此公告。 通策医疗股份有限公司董事会 2025 年 12 月 11 日 1 通策医疗股份有限公司 关于选举职工董事及取消职工监事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《中华人民共和国公司法》《上海证券交易所上市公司自律监管指引第 1 号 ——规范运作》及《上市公司章程指引》等法律法规和规范性文件和经公司股东会审 议通过后的《公司章程（修订案）》的相关规定，公司不再设置监事会、公司董事会 设职工董事一名。通策医疗股份有限公司（以下简称"公司"）于 2025 年 12 月 10 日召开公司职工代表大会，经与会职工代表审议，同意取消周辉先生职工代表监事职 务；同意选举王维倩女士为公司第十届董事会职工董事（ ...

证券代码：600763 证券简称：通策医疗 公告编号：2025-033 通策医疗股份有限公司 2025年第一次临时股东会决议公告 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 12 月 10 日 (二)股东大会召开的地点：杭州市西湖区西溪路双口井巷 1 号通策医疗大厦 7 楼 报告厅 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 543 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 163,135,995 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总 | | | 数的比例（%） | 36.4721 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长王毅女士主持本次股东大会。会议 的召开程序、表决方式等符合《公司法》及《公司章程》的有关规定。本次会议 采取现场结合网络的表决方式。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并 ...

法律意见书 浙江天册律师事务所 关于 通策医疗股份有限公司 2025 年第一次临时股东会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于 通策医疗股份有限公司 2025 年第一次临时股东会的 法律意见书 （一）经本所律师查验，本次股东会由董事会提议并召集，召开本次股东会 的通知已于 2025 年 11 月 25 日在指定媒体及上海证券交易所网站上公告。 （二）本次会议采取现场投票与网络投票相结合的方式。 编号：TCYJS2025H2113 号 致：通策医疗股份有限公司 浙江天册律师事务所（以下简称"本所"）接受通策医疗股份有限公司（以 下简称"通策医疗"或"公司"）的委托，指派本所律师参加公司 2025 年第一 次临时股东会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委 员会《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和 其他有关规范性文件的要求出具本法律意见书。 ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Tongce Medical (600763) as of December 9, 2025, with a closing price of 41.5 yuan, reflecting a decrease of 0.57% [1] - The company reported a main revenue of 2.29 billion yuan for the first three quarters of 2025, showing a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - In the third quarter of 2025, the company achieved a single-quarter main revenue of 842 million yuan, which is a 2.34% increase year-on-year, and a net profit of 192 million yuan, reflecting a 2.31% year-on-year growth [2] Group 2 - The company's debt ratio stands at 25.1%, with investment income reported at 41.22 million yuan and financial expenses at 31.93 million yuan, resulting in a gross profit margin of 41.69% [2] - Over the past 90 days, seven institutions have provided ratings for the stock, with four giving a buy rating and three an increase rating, while the average target price set by institutions is 5.288 billion yuan [2] - On December 9, 2025, the net inflow of main funds was 5.03 million yuan, accounting for 4.05% of the total transaction amount, while retail investors experienced a net outflow of 7.47 million yuan, representing 6.01% of the total transaction amount [1]

Core Viewpoint - Tongce Medical (600763) has shown a slight decline in stock price and mixed capital flow, indicating potential investor caution and varying interest from different types of investors [1][2]. Group 1: Stock Performance - As of December 8, 2025, Tongce Medical closed at 41.74 CNY, down 0.1% with a turnover rate of 0.7% and a trading volume of 31,500 lots, amounting to a total transaction value of 132 million CNY [1]. - Over the past five days, the stock has experienced fluctuations in price and capital flow, with a notable net outflow of 1,098.88 million CNY on December 8, 2025, which accounted for 8.35% of the total transaction value [2]. Group 2: Financial Metrics - Tongce Medical's total market capitalization is 18.67 billion CNY, with a net asset value of 4.703 billion CNY and a net profit of 514 million CNY, ranking 8th, 12th, and 6th respectively within the medical services industry [3]. - The company reported a year-on-year revenue increase of 2.56% for the first three quarters of 2025, totaling 2.29 billion CNY, with a net profit of 514 million CNY, reflecting a 3.16% increase [3]. Group 3: Institutional Ratings - In the last 90 days, eight institutions have provided ratings for Tongce Medical, with five giving a "buy" rating and three an "increase" rating, while the average target price set by institutions is 52.88 CNY [4].

Core Viewpoint - Tongce Medical (600763) shows a slight increase in stock price and mixed capital flow data, indicating potential investor interest and market dynamics [1][2]. Group 1: Stock Performance - As of December 5, 2025, Tongce Medical closed at 41.78 yuan, up 0.48% with a turnover rate of 0.83% and a trading volume of 37,300 hands, resulting in a transaction amount of 154 million yuan [1]. - The capital flow data on December 5 indicates a net outflow of 16.57 million yuan from main funds, accounting for 10.74% of the total transaction amount, while retail investors saw a net inflow of 11.06 million yuan, representing 7.17% of the total [1][2]. Group 2: Recent Capital Flow Trends - Over the past five days, the stock has experienced varying capital flows, with the main funds showing consistent net outflows, while retail investors have generally contributed to net inflows [2]. - On December 4, 2025, the main funds had a net outflow of 7.97 million yuan, and on December 3, the outflow was 18.69 million yuan, indicating a trend of reduced institutional buying [2]. Group 3: Financial Metrics and Industry Comparison - Tongce Medical's total market capitalization is 18.688 billion yuan, with a net asset value of 4.703 billion yuan and a net profit of 514 million yuan, ranking 6th in the medical services industry [3]. - The company reported a gross margin of 41.69% and a net margin of 26.91%, significantly higher than the industry averages of 36.47% and 4.61%, respectively [3]. - For the first three quarters of 2025, the company achieved a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit of 514 million yuan, up 3.16% year-on-year [3]. Group 4: Analyst Ratings - In the last 90 days, 9 institutions have rated the stock, with 6 buy ratings and 3 hold ratings, indicating a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 51.78 yuan, suggesting potential upside from the current trading price [4].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting it to outperform the CSI 300 index by more than 10% in the next six months [4][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 1.25% from November 21 to December 4, 2025, which is approximately 0.85 percentage points lower than the index [4][11]. - Most sub-sectors within the industry recorded negative returns during the same period, with the pharmaceutical distribution and offline pharmacy sectors showing positive growth of 4.18% and 0.37%, respectively. In contrast, the medical research outsourcing and vaccine sectors experienced declines of 4.57% and 4.45% [4][12]. - Approximately 35% of stocks in the industry recorded positive returns, while about 65% saw negative returns during the reporting period [4][13]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 51.20 times as of December 4, 2025, indicating a decline in industry valuation [4][17]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 1.25% from November 21 to December 4, 2025 [11]. - Most sub-sectors recorded negative returns, with pharmaceutical distribution and offline pharmacies performing relatively well [12]. - About 35% of stocks in the industry had positive returns, while 65% had negative returns [13]. - The industry valuation has decreased, with a PE ratio of 51.20 times [17]. 2. Industry News - The report highlights significant industry news, including the announcement of centralized procurement results for medical consumables in Liaoning Province, which included 799 products [24]. - The report also mentions the release of the "Clinical Blood Use Technical Specifications (2025 Edition)" by the National Health Commission [20]. 3. Company Announcements - Dongcheng Pharmaceutical announced that its subsidiary received a production license for radioactive pharmaceuticals, which is not expected to significantly impact current performance [25]. 4. Weekly Industry Outlook - The report maintains an "Overweight" rating for the industry, suggesting a focus on investment opportunities in the flu-related sector due to increased flu cases compared to the previous year [26][29]. - Recommended stocks include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, scientific services, and traditional Chinese medicine [26][29].

Core Viewpoint - Tongce Medical (600763) emphasizes its commitment to solid operations and management to repay investors' trust while continuously monitoring market conditions [1] Company Summary - The management of Tongce Medical is focused on maintaining awareness of market conditions [1] - The company aims to enhance its operational performance to build investor confidence [1]